DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Pertuzumab
Pertuzumab
Pertuzumab and Trastuzumab: the Rationale Way to Synergy
Refreshing the Biologic Pipeline 2020
Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy
Colony Stimulating Factors
Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy
Modifications to the Harmonized Tariff Schedule of the United States To
Changing the Destiny of HER2 Expressing Solid Tumors
The Two Tontti Tudiul Lui Hi Ha Unit
HER-Targeted Tyrosine Kinase Inhibitors Enhance Response to Trastuzumab and Pertuzumab in HER2-Positive Breast Cancer
Antibodies for the Treatment of Brain Metastases, a Dream Or a Reality?
Perjeta Full Prescribing Information
Medical Drug Benefit Clinical Criteria Updates
Exposure-Response Analyses of Ramucirumab from Two
Journal of Managed Care & Specialty Pharmacy®
I Regulations
Prevention and Treatment of Acneiform Rash in Patients Treated with EGFR Inhibitor Therapies Effective Date: November, 2020
Anti-HER2 Therapies: When More Is More
(INN) for Biological and Biotechnological Substances
Top View
Name of Policy: Perjeta® (Pertuzumab)
HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer
Skin Care During Treatment with Epidermal Growth Factor Receptor Inhibitors (Egfri)
(Trastuzumab-DM1) for Treatment of HER-2 Positive Malignancies
"Use of This Document Is Governed by the Terms of Use on the First Page of This Document." # Section Comments 2020
(CHMP) Agenda for the Meeting on 17-20 May 2021 Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes
INN Working Document 05.179 Update December 2010
Pertuzumab for Treatment of Malignancies
(Oncology & Haematology) Made in Its 110Th Meeting Held On
Update on Molecular Pathology and Role of Liquid Biopsy in Nonsmall Cell Lung Cancer
Potential and Applications of Nanocarriers for Efficient Delivery Of
International Nonproprietary Names (Inn) for Biological and Biotechnological Substances
(INN) for Biological and Biotechnological Substances
Development Beyond Breast Cancer
Current Status and Future Directions of Targeted Agents and Immunotherapy in Gastric Cancer
PERJETA Dosing and Administration Guide
Blue Cross and BCN Utilization Management Medical Drug List
And Phesgo (Pertuzumab Trastuzumab And